This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Sanofi-Aventis. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Heloise Audat: Innovator in Multiple Myeloma Treatment
Introduction
Heloise Audat is a prominent inventor based in Paris, France. She has made significant contributions to the field of medicine, particularly in the treatment of multiple myeloma. Her innovative approaches have the potential to improve the lives of many patients suffering from this challenging condition.
Latest Patents
Heloise Audat holds a patent for her groundbreaking work titled "Methods of treating multiple myeloma." This patent outlines methods for treating refractory multiple myeloma or relapsed and refractory multiple myeloma in individuals who have undergone at least two prior therapies. The methods involve administering an anti-CD38 antibody, pomalidomide, and dexamethasone. Additionally, her patent includes methods aimed at improving renal impairment in individuals diagnosed with multiple myeloma.
Career Highlights
Heloise Audat is currently associated with Sanofi-Aventis, a leading global biopharmaceutical company. Her work at Sanofi-Aventis has allowed her to collaborate with other experts in the field and contribute to the advancement of innovative treatments for complex diseases.
Collaborations
Heloise has worked alongside talented colleagues, including Audrey Bonestebe and Frank Campana Zambrano. These collaborations have fostered a dynamic environment for research and development, enhancing the potential for impactful medical breakthroughs.
Conclusion
Heloise Audat's contributions to the treatment of multiple myeloma exemplify the importance of innovation in medicine. Her patent and ongoing work at Sanofi-Aventis highlight her commitment to improving patient outcomes. Through her efforts, she continues to pave the way for advancements in cancer treatment.